RSMDF Quote, Financials, Valuation and Earnings

VolitionRX has a net margin of 28.26% compared to ResMed's net margin of -2201.34%. ResMed's return on equity of 25.76% beat VolitionRX's return on equity of --.

ResMed has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 362.44%. Given that VolitionRX has higher upside potential than ResMed, analysts believe VolitionRX is more attractive than ResMed.

ResMed has a beta of 0.625, which suggesting that the stock is 37.542% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

ResMed has a quarterly dividend of $0.05 per share corresponding to a yield of 0.96%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than VolitionRX quarterly revenues of $246.4K. ResMed's net income of $365M is higher than VolitionRX's net income of -$5.4M. Notably, ResMed's price-to-earnings ratio is 24.69x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.46x versus 43.82x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 28.26% compared to ResMed's net margin of -2828.67%. ResMed's return on equity of 25.76% beat Catheter Precision's return on equity of -137.84%.

ResMed has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 447.95%. Given that Catheter Precision has higher upside potential than ResMed, analysts believe Catheter Precision is more attractive than ResMed.

ResMed has a beta of 0.625, which suggesting that the stock is 37.542% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.850, suggesting its less volatile than the S&P 500 by 184.968%.

ResMed has a quarterly dividend of $0.05 per share corresponding to a yield of 0.96%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Catheter Precision quarterly revenues of $143K. ResMed's net income of $365M is higher than Catheter Precision's net income of -$4M. Notably, ResMed's price-to-earnings ratio is 24.69x while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.46x versus 4.19x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 28.26% compared to ResMed's net margin of 0.18%. ResMed's return on equity of 25.76% beat Xtant Medical Holdings's return on equity of -26.62%.

ResMed has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that Xtant Medical Holdings has higher upside potential than ResMed, analysts believe Xtant Medical Holdings is more attractive than ResMed.

ResMed has a beta of 0.625, which suggesting that the stock is 37.542% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

ResMed has a quarterly dividend of $0.05 per share corresponding to a yield of 0.96%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. ResMed's net income of $365M is higher than Xtant Medical Holdings's net income of $58K. Notably, ResMed's price-to-earnings ratio is 24.69x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.46x versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.